RLMD - Relmada Therapeutics

-

$undefined

N/A

(N/A)

Relmada Therapeutics NasdaqGS:RLMD Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Location: 2222 Ponce de Leon Blvd., Coral Gables, FL, 33134, United States | Website: https://www.relmada.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-3.107M

Cash

27.06M

Avg Qtr Burn

-14.2M

Short % of Float

4.97%

Insider Ownership

17.03%

Institutional Own.

33.47%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NDV-01 Details
Non-muscle invasive bladder cancer

Phase 2

Update

Sepranolone Details
Tourette syndrome

Phase 2

Initiation

Sepranolone Details
Prader Willi syndrome

Phase 2

Initiation

REL-P11 Details
Obesity, Metabolic disorder

Phase 1

Update

Psilocybin (REL-P11) Details
Obesity, Metabolic disorder

Phase 1

Initiation

REL-1017 Details
Major depressive disorder, Mental health

Failed

Discontinued